Moleculin Biotech Inc (MBRX)
2.75
+0.31
(+12.70%)
USD |
NASDAQ |
Sep 27, 16:00
2.72
-0.03
(-1.09%)
After-Hours: 20:00
Moleculin Biotech SG&A Expense (Annual): 10.02M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.02M |
| December 31, 2022 | 11.54M |
| December 31, 2021 | 8.386M |
| December 31, 2020 | 6.785M |
| Date | Value |
|---|---|
| December 31, 2019 | 6.312M |
| December 31, 2018 | 5.229M |
| December 31, 2017 | 4.09M |
| December 31, 2016 | 2.381M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
6.312M
Minimum
2019
11.54M
Maximum
2022
8.608M
Average
8.386M
Median
2021
SG&A Expense (Annual) Benchmarks
| Agilent Technologies Inc | 1.634B |
| Seelos Therapeutics Inc | 12.58M |
| Cara Therapeutics Inc | 27.65M |
| Citius Pharmaceuticals Inc | 21.91M |
| NovaBay Pharmaceuticals Inc | 12.83M |